A new publication authored by multiple members of the RID Program, including Dr. Elisabeth McClymont, Dr. Jeffrey Wong, Sandra Blitz and Dr. Deborah Money has been published in Vaccine! This publication entitled “Acceptance and preference between respiratory syncytial virus vaccination during pregnancy and infant monoclonal antibody among pregnant and postpartum persons in Canada” describes findings from the second iteration of the COVERED Project, wherein Canadian pregnant women and people (19 years of age and older), of varying COVID-19 vaccination status, completed a series of online questionnaires that assessed the effectiveness, outcomes, perception, and immunogenicity (if applicable) of COVID-19 vaccines in pregnancy. The data described in this publication corresponds to participants who completed these surveys between September of 2023 and March of 2024. This publication specifically focused on the findings from these participants regarding preferences between maternal vaccination for RSV in pregnancy and infant monoclonal antibody treatment, as well as general attitudes and acceptance of these immunization strategies. Key findings included 79% of participants recording that if offered at least one immunization strategy they would take it, with 77% willing to accept RSV vaccination in pregnancy, and 55% willing to accept infant monoclonal antibody treatment. RSV vaccination in pregnancy was highly preferred over infant antibody treatment, with 77% preferring maternal vaccination, compared to 4.4% preferring monoclonal antibody, and 14% having no preference between either immunization strategy. For more information and to read more about these and other findings, access the publication here!